Background Interstitial fibrosis in lupus nephritis (LN) is often infiltrated by immune cells but typically regarded as ...

Objective The question of sustained remission in SLE has been highlighted recently following data published on the use of ...

Objective Lupus nephritis (LN) is a prevalent renal manifestation in patients with SLE, with kidney biopsy remaining the gold ...

Despite advancements in lupus management over the past two decades, infection remains a significant cause of morbidity and mortality among patients with systemic lupus erythematosus (SLE). 1 2 Various ...

Bone involvement is a common cause of morbidity and disability in systemic lupus erythematosus (SLE). 1 This is both a consequence of the disease itself and treatments, including steroids. 2 As ...

Systemic lupus erythematosus (SLE) is a severe autoimmune disease characterized by persistent damage to multiple organs and tissues, including the skin, kidneys, cardiovascular system, and brain.

Understanding the factors contributing to poor treatment adherence, recognizing its consequences, and developing effective strategies to enhance adherence are key to improving patient outcomes in ...

A key lupus outcome measure is the assessment of damage, which is considered as a separate domain to disease activity and health related quality of life and has been shown to independently predict ...

Systemic lupus erythematosus (SLE) is associated with a wide variety of ocular manifestations. Some of these include uveitis, occlusive retinal vasculitis, (epi)scleritis and keratitis. Uveitis is an ...

Hemophagocytic lymphohistiocytosis (HLH) is a well-recognised complication of systemic lupus erythematosus (SLE). In one small case series, HLH was noted in approximately 5% of patients with lupus. 1 ...

Background Lupus is a complex autoimmune disease characterized by loss of self-tolerance, leading to dysregulated functions of T and B cells. Broadly increased glucose metabolism has been reported in ...

Methods Secondary data analysis from a convenience sample of 100 cSLE followed every 3 months for up to 7 visits. 1 Ratings of PhGA 0–10, PhGA 0–3, parent assessment of patient well- being (ParGA; ...